EICHORPublic-registry site landscape for NCT07753850, “A Phase 2 Study of SL-325 in Crohn's Disease Patients”, a Crohn's Disease study sponsored by Shattuck Labs, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07753850 (registry record) |
| Study title | A Phase 2 Study of SL-325 in Crohn's Disease Patients |
| Official title | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SL-325 in Participants With Moderately to Severely Active Crohn's Disease |
| Sponsor | Shattuck Labs, Inc. |
| Condition(s) | Crohn's Disease |
| Phase | PHASE2 |
| Listed sites | 0 |
| Intervention(s) | SL-325, Placebo |
Patient-friendly overview of this study: eichor.com/study/NCT07753850.
Eichor generates a preliminary site-risk snapshot for NCT07753850 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Crohn's Disease trials
← Eichor home · All tracked trials · Crohn's Disease studies · Weekly briefs
